IVD China last week: Mindray, Agilent and Majorbio, AmoyDx, Novogene & BD

Mindray Listed in 2024 Fortune China 500

On July 25, the Fortune China 500 list was released, with a total of 15 pharmaceutical companies making the list. China National Pharmaceutical Group Corporation ranked 34th with a revenue of $96.0722 billion, while Mindray ranked 408th with a revenue of $4.934 billion. The Fortune China 500 list uses the same ranking methodology as the Fortune Global 500, including both listed and non-listed companies. The 500 Chinese companies on the list had a total revenue of $14.6 trillion in 2023, a decrease of about 3% compared to the companies on the list last year; net profits reached $706.4 billion, a decrease of about 1.5% from the previous year.

Majorbio Forms Strategic Partnership with Agilent

On July 22, Shanghai Majorbio Bio-Pharm Technology Co.,Ltd. and Agilent Technologies Inc. announced a strategic partnership "Agilent Sample Quality Control Certification Laboratory." Majorbio's General Manager Han Jichen and Agilent's Assistant Vice President and Sales General Manager of Diagnostics, Genomics, and Cell Analysis Division in Greater China, Li Jian, jointly witnessed the ceremony. This collaboration will leverage Agilent's high standards and Majorbio 's multi-omics research services, providing comprehensive and efficient one-stop omics solutions for researchers.

AmoyDx's Products Approved in Japan for Two MET Companion Diagnostics

The Ministry of Health, Labour and Welfare of Japan has consecutively approved two new indications for AmoyDx's rapid lung cancer multi-target screening product, AMOEJ™ (also known as the PCR-11 gene product). These approvals are for use as companion diagnostics for Novartis' Capmatinib and Haihe Pharma's Glumetinib, two innovative targeted drugs. They are intended to guide precise treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations.

Novogene and BD Establish Single-Cell Multi-Omics Joint Laboratory

Novogene and BD held a signing ceremony for the "Single-Cell Instrument HT Xpress". Jiang Wenkai, Deputy General Manager of Novogene's Global Scientific Services Product Center, and Liu Chunhai, Head of BD's Biosciences Single-Cell Platform, attended the ceremony. During the signing ceremony, both parties discussed future cooperation directions in single-cell multi-omics research. By integrating their resources, they aim to promote the application of single-cell multi-omics technology, bringing more robust technical support to single-cell research and advancing the field of single-cell multi-omics.